Heat shock protein 47 in blood clot conditions
Official title: Heat Shock Protein 47: A Novel Biomarker of Thrombosis Risk
Run by University of Aarhus · NCT06731673 · Data updated 2026-11-12
This will test whether platelet levels of Heat Shock Protein 47 (HSP47) can help predict outcomes in adults with recent venous thromboembolism, ST-elevation myocardial infarction, or ischemic stroke compared with healthy volunteers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 340 (estimated) |
| Sponsor | University of Aarhus Academic / other |
| Locations | 2 sites (Aarhus, Central Region and 1 other locations) |
| Status | Recruiting |
| Started | December 9, 2024 |
| Main results expected | August 31, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | August 21, 2025 |
| Trial ID | NCT06731673 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with confirmed DVT or PE, ST-elevation myocardial infarction with a culprit coronary lesion on angiography, or ischemic stroke with atrial fibrillation and the specified imaging features who can give informed consent are ideal candidates.
✕Probably not a fit
People with known hematological disorders, active hematological malignancy, severe renal failure (eGFR <15 or on dialysis), incidental PE without DVT, or who do not meet the acute event definitions are unlikely to benefit from this biomarker-focused protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will measure platelet HSP47 levels in adults presenting with acute VTE, ST-elevation myocardial infarction, or ischemic stroke and compare them to healthy volunteers. Patients will provide blood samples at diagnosis and again at 3 and 12 months, while healthy volunteers give a single sample. The study will compare acute versus follow-up HSP47 levels and examine associations between HSP47, platelet function, and fibrinolytic capacity. The work is conducted at participating centers in Denmark and Germany.
Why it matters
Potential benefit: If HSP47 reliably marks thrombotic activity, it could help identify patients at higher risk of recurrent clots and guide monitoring or preventive treatment.
How similar studies have gone: HSP47 has been studied in fibrosis and platelet biology but has not been widely validated as a clinical prognostic biomarker for thrombotic disease, so this is a relatively novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Informed consent VTE group: * Deep vein thrombosis confirmed on ultrasonography OR * Pulmonary embolism confirmed on computed tomography angiography (CTA) AMI group: * ST-segment elevation on electrocardiogram (ECG) AND * Culprit lesion(s) on coronary angiography Stroke group: * Stroke confirmed on magnetic resonance imaging AND * Atrial fibrillation (Detected on ECG, telemtry or Holter monitoring) AND * Stroke localisation classic for AFib: cortical, cerebellar, brainstem or subcortical \>1.5 cm in diameter Healthy group: \- Healthy Exclusion Criteria: * \<18 years of age * no informed consent * Known haematological disorders * Active haematological malignancy * Severe renal insufficiency defined as eGFR \<15 or dialysis VTE - Pulmonary embolism incidentally detected by CTA conducted for purposes unrelated to pulmonary embolism assessment without concomitant DVT AMI * Coronary dissection * Takotsubo cardiomyopathy Stroke \- Stroke from other causes, e.g. findings pointing towards large vessel disease Healthy * Known acute or chronic disease * Prior VTE, AMI, stroke or other thromboembolic event
Where it's running
-
Aarhus University Hospital
Aarhus, Central Region, Denmark Recruiting -
Deutsches Herzzentrum de Charité
Berlin, State of Berlin, Germany Recruiting
Study contacts
- Study coordinator: Kathrine A Friis, MD, PhD-fellow
- Email: katfrs@rm.dk
- Phone: +45 20 65 27 32
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
TRiP-cast score test in adults with acute lower-limb injuries requiring immobilization
This study tests whether the TRiP(cast) score can predict risk of blood clots in adults with acute lower-limb injuries treated as outpatients.
-
Pulmonary Embolism Registry from Emergency Care to Long-Term Follow-Up
This registry follows adults with acute pulmonary embolism to see how care is given in the real world and what happens over time.
-
YKYY033 Injection safety and tolerability in adults
This study tests whether a single dose of YKYY033 injection is safe and tolerable in healthy adults aged 18–55.
-
Blood-clot prevention with REGN7508 and REGN9933 in people with PICC lines
This study tests whether REGN7508 and REGN9933 can help prevent blood clots in people who have a PICC line.
-
Treatment and prevention of blood clots in adults with cancer
This study tests REGN7508 against apixaban to see if it can treat and prevent blood clots in adults with or without cancer, including those with cancer-related clots in the legs and lungs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.